Regencell bioscience holdings limited announces over $1 million ordinary share purchase by ceo

Hong kong--(business wire)--regencell bioscience holdings limited (nasdaq: rgc) (“regencell” or the “company”), an early-stage bioscience company focuses on the research, development and commercialization of tcm for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that yat-gai au, the company's chairman & ceo, made ordinary share purchases of regencell (“ordinary shares”) totaling $1,125,807. as per the s
RGC Ratings Summary
RGC Quant Ranking